APIM Therapeutics AS

APIM Therapeutics AS is a clinical-stage biotech company developing first-in-class peptide drugs against multiple cancers. The drug targets the PCNA/APIM stress switch, a novel intervention point controlling cellular stress responses (e.g. DNA Damage Response). The approach is based on research from the University of Science and Technology, NTNU, Trondheim, and allows for the potentiation of the action of >25 clinical drugs across multiple cancer indications. ATX-101, the company’s current lead, has shown strong preclinical proof-of-efficacy in preclinical models of bladder, breast, multiple myeloma, AML and prostate cancer in combination with several anti-cancer drugs. For further information, please visit: www.apimtherapeutics.com